This week there’s more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.
Company has said it will offer doses at a not-for-profit cost to provide global access to the vaccine.
The vaccine candidate contains the Company’s saponin-based Matrix-M™ adjuvant technology to enhance immune response.
GlaxoSmithKline and Sanofi Pasteur will supply 100 million doses of its experimental vaccine to the US.
To combat the surging pandemic, Fauci is calling on all Americans to practice social distancing and wearing masks.
It’s been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There’s results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting SARS-CVv-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
Vaccination with mRNA-1273, Moderna’s coronavirus disease 2019 (COVID-19) vaccine candidate, led to robust immune responses and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in nonhuman primates.
Expansion of population restrictions, allergies most common safety issues triggering labeling changes.
Pfizer and BioNTech have selected a coronavirus disease 2019 (COVID-19) vaccine candidate and have initiated their phase 2/3 safety and efficacy trial.
